In Vitro Antiprotozoal Effects of Nano-chitosan on Plasmodium falciparum, Giardia lamblia and Trichomonas vaginalis

Elmi, Taher; Esboei, Bahman Rahimi; Sadeghi, Fatemeh; Zamani, Zahra; Didehdar, Mojtaba; Fakhar, Mahdi; Chabra, Aroona; Hajialiani, Fateme; Namazi, Mohammad Javad; Tabatabaie, Fatemeh

doi:10.1007/s11686-020-00255-6

Cited by 16 publications

(18 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The combination of miconazole and farnesol in CNPs expressed a greater antifungal effect in vivo [289] Argentinean medicinal plants Chitosan microcapsules containing active substances exhibited strong antifungal capacity in vitro [290] Bacterial vaginosis Doxycycline CNP-associated doxycycline expressed a significant reduction in E. coli viability in vitro [291] Metronidazole Superior in vitro inhibition of B. fragilis growth by chitosan-alginate microspheres containing metronidazole [265] Aerobic vaginitis Cefixime Cefixime microspheres reduced E. coli viability in vitro [292] Trichomoniasis -CNPs expressed concentrations and time-dependent antimicrobial activity against T. vaginalis in vitro [293] Table 3. Cont.…”

Section: Candidiasismentioning

confidence: 99%

“…Chitosan with beneficial properties for healthcare applications can be obtained from fungi, as an alternative to the commonly used marine source [21]. Elmi et al developed CNPs with chitosan obtained from Penicillium fungi and evaluated their in vitro antimicrobial effect against T. vaginalis [293]. Compared with the antimicrobial drug metronidazole, applied as positive control, the effectiveness of CNPs was dependent on the polymer concentration and duration of the exposure.…”

Section: Particles and Carriersmentioning

confidence: 99%

See 1 more Smart Citation

The Expanded Role of Chitosan in Localized Antimicrobial Therapy

2021

View full text Add to dashboard Cite

Chitosan is one of the most studied natural origin polymers for biomedical applications. This review focuses on the potential of chitosan in localized antimicrobial therapy to address the challenges of current rising antimicrobial resistance. Due to its mucoadhesiveness, chitosan offers the opportunity to prolong the formulation residence time at mucosal sites; its wound healing properties open possibilities to utilize chitosan as wound dressings with multitargeted activities and more. We provide an unbiased overview of the state-of-the-art chitosan-based delivery systems categorized by the administration site, addressing the site-related challenges and evaluating the representative formulations. Specifically, we offer an in-depth analysis of the current challenges of the chitosan-based novel delivery systems for skin and vaginal infections, including its formulations optimizations and limitations. A brief overview of chitosan’s potential in treating ocular, buccal and dental, and nasal infections is included. We close the review with remarks on toxicity issues and remaining challenges and perspectives.

show abstract

Section: Candidiasismentioning

confidence: 99%

Section: Particles and Carriersmentioning

confidence: 99%

The Expanded Role of Chitosan in Localized Antimicrobial Therapy

2021

View full text Add to dashboard Cite

show abstract

“…The authors demonstrated the anti-T. vaginalis activity of nano-chitosan, with particles slightly less than 100 nm, presenting an IC 50 of 11 µg/mL. The nanoencapsulated form of chitosan impaired trophozoite viability up to 99.4% within 48 h of exposure, while the same concentration of chitosan was able to cause a 64.7% mortality rate [106].…”

Section: Articles: Nanotechnologymentioning

confidence: 98%

Novel Treatment Approaches to Combat Trichomoniasis, a Neglected and Sexually Transmitted Infection Caused by Trichomonas vaginalis: Translational Perspectives

et al. 2022

View full text Add to dashboard Cite

The multistep translational science behind new drugs comprehends the entire process through laboratory, clinical, and community observations turned into health interventions. The development of new drug options from discovering targets and leading compounds in basic research for implementing therapeutic guidelines contributes to the emergence of health policies essential for infection control. This review updates the translational research in the scenario of the most common non-viral sexually transmitted infection (STI), trichomoniasis. Paradoxically to its high occurrence, it is considered neglected since notification is not mandatory. It turns into a stable disease with health complications, and receives little emphasis from public health programs to control STI. Although related to curable STIs, the current drugs, metronidazole and tinidazole, present therapeutic failures. The need for new options to treat trichomoniasis is established by basic research studies and patents revealing novel synthetic compounds and natural products presenting anti-Trichomonas vaginalis activities, mainly based on in vitro findings. Clinical trials are still focused on new routes of administration for conventional drugs. In addition, nanotechnology approaches are in their infancy, shedding light on potential possibilities for creating more effective, targeted, and safe delivery systems. Overall, the novel proposed approaches need, in addition to pharmaceutical development and efficacy assessments, to ensure that the quality requirements for their use as medicines are met. It is essential to overcome these issues to cross the “Death Valley” of drug discovery and to advance in the translational science criteria in the trichomoniasis drug development field.

show abstract

“…In the study conducted byElmi et al (2020), CNPs synthesized by Penicillium fungi at the dose of 50 μg/ml after 180 min exposure eliminated 31.3% of G. lamblia cysts[19] Said et al (2012). also showed that synthesized CNPs prepared by ionic crosslinking of chitosan solution at the dose of 5 ppm for 8 d significantly reduced the number of Giardia cysts in the stool and trophozoites in intestinal sections of rats with giardiasis[16].Recently, El-Gendy et al (2021) demonstrated that oral administration of CNPs at the dose of 50µg/hamster/day for 7 consecutive days alone and especially in combination with MTZ in Syrian hamsters infected with G. lamblia significantly reduced the cysts and trophozoites counts by 63.64-94.69%.…”

mentioning

confidence: 98%

Applying Nanoparticles for Treating Giardia Infection: A Systematic Review

et al. 2021

View full text Add to dashboard Cite

At present, chemotherapy with some drugs such as nitroimidazoes derivatives is the preferred treatment for giardiasis. However, these agents are associated with adverse side effects ranging from nausea to possible genotoxicity. The present investigation was designed to systematically review the in vitro, in vivo, and clinical studies about the efficacy of nanoparticles against giardiasis. The study was carried out based on the 06-PRISMA guideline and registered in the CAMARADES-NC3Rs Preclinical Systematic Review and Meta-analysis Facility (SyRF) database. The search was performed in five English databases, including Scopus, PubMed, Web of Science, EMBASE, and Google Scholar, without time limitation for publications around the world about anti-Giardia effects of all organic and inorganic nanoparticles without date limitation in order to identify all the published articles. The searched words and terms were “Giardiasis”, “Giardia lamblia”, “Giardia intestinalis”, “Giardia duodenalis”, “nanoparticles”, “nanomedicine”, “in vitro”, in vivo”, and “clinical trial”. Out of 312 papers, 10 papers, including 4 in vitro (40.0%), 5 in vivo (50.0%), and 1 in vitro/in vivo (10.0%) up to 2021 met the inclusion criteria for discussion in this systematic review. The most common type of nanoparticles was metal nanoparticles (5 studies, 50.0%) such as silver, gold, etc., followed by organic nanoparticles such as chitosan nanoparticles (4 studies, 40.0%). The results of this review study showed the high efficacy of a wide range of organic and non-organic NPs against giardiasis, indicating that nanoparticles could be considered as an alternative and complementary resource for treating giardiasis, since they have no significant toxicity. However, more studies are required to elucidate this conclusion, especially in clinical systems.

show abstract

In Vitro Antiprotozoal Effects of Nano-chitosan on Plasmodium falciparum, Giardia lamblia and Trichomonas vaginalis

Cited by 16 publications

References 45 publications

The Expanded Role of Chitosan in Localized Antimicrobial Therapy

The Expanded Role of Chitosan in Localized Antimicrobial Therapy

Novel Treatment Approaches to Combat Trichomoniasis, a Neglected and Sexually Transmitted Infection Caused by Trichomonas vaginalis: Translational Perspectives

Applying Nanoparticles for Treating Giardia Infection: A Systematic Review

Contact Info

Product

Resources

About